- Adds significant strategic biotech business experience -
CAMBRIDGE, Mass., May 12 /PRNewswire-FirstCall/ -. Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced the appointment of John F. Dee to its Board of Directors. The Company also announced that Geoffrey Hazlewood, Ph.D., Senior Vice President of Research, has resigned for personal reasons effective May 31, 2008 and will be returning to his native England. Dr. Hazlewood will remain as an exclusive consultant to the Company and will also join its scientific advisory board, enabling him to play an ongoing role in bringing many of Verenium's important research projects to a successful conclusion.
"We are very pleased that John has joined the Verenium Board, as his extensive executive-level experience working with emerging-growth companies in strategic, financial and operational development will contribute valuable perspective while the Company rapidly accelerates into a commercial-scale producer of next-generation biofuels," said Carlos A. Riva, President and Chief Executive Officer at Verenium. "I'd also like to thank Geoff Hazlewood for his many years of significant service and contributions to Verenium and look forward to his continuing involvement."
Mr. Dee served as President, Chief Executive Officer, and Director of
Hypnion, Inc., a privately-held neurosciences drug discovery company, from
its founding in July 2000 through its $315 million acquisition by Eli Lilly
and Company in April 2007. Before Hypnion, Mr. Dee spent three years as a
"turn- around" CEO, specializing in reviving under-performing biotechnology
companies including Genta, Inc. Prior
|SOURCE Verenium Corporation|
Copyright©2008 PR Newswire.
All rights reserved